Molecular targeted therapies in hepatocellular carcinoma

Josep M. Llovet, Jordi Bruix – 26 September 2008 – Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor with several genomic alterations. There is evidence of aberrant activation of several signaling cascades such as epidermal growth factor receptor (EGFR), Ras/extracellular signal‐regulated kinase, phosphoinositol 3‐kinase/mammalian target of rapamycin (mTOR), hepatocyte growth factor/mesenchymal‐epithelial transition factor, Wnt, Hedgehog, and apoptotic signaling. Recently a multikinase inhibitor, sorafenib, has shown survival benefits in patients with advanced HCC.

Improved outcomes in patients with hepatitis C with difficult‐to‐treat characteristics: Randomized study of higher doses of peginterferon α‐2a and ribavirin

Michael W. Fried, Donald M. Jensen, Maribel Rodriguez‐Torres, Lisa M. Nyberg, Adrian M. Di Bisceglie, Timothy R. Morgan, Paul J. Pockros, Amy Lin, Lisa Cupelli, Frank Duff, Ka Wang, David R. Nelson – 26 September 2008 – Treatment response remains suboptimal for many patients with chronic hepatitis C, particularly those with genotype 1 and high levels of viremia. The efficacy of high‐dose regimens of peginterferon alfa‐2a and ribavirin was compared with conventional dose regimens in patients with features predicting poor treatment responses.

Subscribe to